SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to community excitement around its real-world brand initiatives, including energy drinks, merchandise, and sponsored events, fostering strong community engagement and IRL presence. The community is actively discussing these initiatives, along with the project's expansion and potential for significant growth, expressing strong conviction and encouraging others to join. Discussions also include updates on holder counts and on-chain metrics, alongside continued building efforts.

Concordium is the Layer-1 blockchain built for a new era of digital trust. With mandatory, privacy-preserving identity verification built into its consensus layer, utilizing zero-knowledge proof technology. Concordium also enables Protocol-level tokens that eliminate smart contract risks by being issued directly at the consensus layer, with built-in features that provide the infrastructure for compliance-ready use cases. At its core is Smart Money - programmable, identity-embedded, and compliance-ready value that powers trusted interactions across Web3. Smart Money enables frictionless exchange, automation, and verifiable trust by design. Unlike conventional blockchains, Concordium integrates trust, accountability, and privacy into its architecture from the ground up  bridging traditional systems and Web3 to build a transparent, sustainable digital future. The name Concordium comes from the Latin concordia—meaning harmony and agreement—a reflection of its mission to build infrastructure that embeds trust, privacy, and compliance into every interaction.

Concordium

Concordium ($CCD) is trending as community members highlight its focus on privacy, compliance, and real-world utility, positioning it as a key infrastructure play for stablecoins and PayFi. Recent partnerships, including integration with bitcoin.com wallets, are also sparking increased interest and bullish sentiment. The community believes its unique approach to verifiable trust and on-chain identity is setting it up for significant growth.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with community members highlighting a recent price pump, while others suggest it's a bull trap. Discussions include potential breakouts, comparisons to other cryptocurrencies, and speculation about future price targets. Some community members point to Litecoin's fundamentals and adoption as reasons for optimism.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as traders discuss its recent price surge and potential pullback, with many viewing dips as buying opportunities. The community is actively debating price targets, with some expecting a significant run, possibly fueled by developments in AI integration and its potential as a decentralized cloud platform. Some are comparing it to previous altcoin pumps, while others believe in its long-term potential.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors assess its current valuation following earnings, with community members debating future growth potential and buyback strategies. Despite strong fundamentals and a reiterated revenue outlook, some express frustration with the stock's recent performance and discuss potential catalysts. Bullish sentiment persists among long-term holders who anticipate a substantial price increase, while others speculate about a possible takeover.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com ($MNDY) is trending due to a significant drop despite recent earnings, sparking debates about AI's potential impact and the company's future growth. Community discussions revolve around whether the stock is oversold and if a rebound is likely, with some citing analyst ratings and potential buyback programs. Others express concerns about cash flow and competition, questioning the long-term investment viability.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is trending as the community focuses on its position as the primary DEX on Coinbase's Base network, with discussions around future integrations and revenue potential driving bullish sentiment. Many believe that the integration positions AERO to reach new all-time highs. Some users are drawing comparisons to Binance's BNB token, speculating on a similar trajectory for AERO.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Uniswap ($UNI) is trending as the community discusses its potential for growth, driven by high annualized fees and strong fundamentals. The recent launch of the Ethereum Protocol Advocacy Alliance, aimed at shaping crypto regulation, is also sparking interest. Traders are closely watching for breakout opportunities and fee-sharing developments.

Monero

Monero is gaining attention as discussions around privacy in crypto intensify, with some community members touting XMR as the only true privacy coin with real-world usage. Despite underperforming Bitcoin recently, some analysts suggest a bullish chart pattern and expect a corrective bounce. Community members are actively discussing its potential to outperform other cryptocurrencies and its role in a future where privacy is paramount.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as the community discusses its potential, driven by buzz around tokenization and real-world asset (RWA) applications. Some traders are eyeing key resistance levels, while others speculate on the impact of potential treasury-related news and partnerships. Despite recent volatility, there's a sense of optimism about AVAX's long-term prospects within the broader crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altimmune (NASDAQ:ALT) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Altimmune (NASDAQ:ALT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29...

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT Altimmune, Inc. Securities Fraud Class Action Lawsuit...

Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease characterized by fat accumulation in the liver accompanied by inflammation and cell damage.The trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes. F2 and F3 fibrosis refer to stages of liver fibrosis, with F2 indicating moderate scarring and F3 indicating severe scarring.Up to 59.1% patients enrolled in the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-impact-phase-2b">study</a> achieved MASH resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.However, the percentage of participants in the trial who achieved fibrosis improvement without worsening of MASH in an intent-to-treat analysis as compared to placebo was not statistically significant.Furthermore, only a total of 25.8% and 24.1% of participants receiving pemvidutide 1.2 mg and 1.8 mg, respectively, achieved the endpoint of both MASH resolution and fibrosis improvement, versus 13.5% in participants receiving placebo.Treatment with the drug, however, resulted in weight loss, with a mean weight loss of up to 6.2% in Pemvidutide-treated participants, compared to 1.0% in the placebo arm.Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication, the company said.Scott Harris, Chief Medical Officer of Altimmune, expressed optimism about the company holding an end-of-mid-stage trial meeting with the FDA in the fourth quarter of 2025 and rapid progression to late-stage trials following the data.Pemvidutide is an investigational drug in development for the treatment of MASH, obesity, Alcohol Use Disorder (AUD), and Alcohol-associated Liver Disease (ALD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALT">Altimmune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_26_at_8_59_53_AM_png_cf1065258b.webp" alt="ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits" width="626" height="66"><figcaption>ALT's Sentiment Meter and Message Volume as of 9:00 a.m. ET on June 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the fibrosis improvement data, which was the only thing “worth looking forward to”, was poor, and they see no ground to start a position.<stembedurl>https://stocktwits.com/Ag035/message/619068912</stembedurl>ALT stock is down by 54% this year and by 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-recalls-over-62000-silverado-trucks-in-us-over-fire-concerns/chmOVMWRR4j">General Motors Recalls Over 62,000 Silverado Trucks In US Over Fire Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Altimmune Stock Plummets After Mixed Results In Liver Disease Trial: Retail Sees ‘Nothing Of Substance’ To Start A Position

Altimmune, Inc. (ALT) on Thursday said that its mid-stage study of Pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) yielded mixed results, sending shares down 57% in morning trade.

Equity

Up to 59.1% patients enrolled in the study achieved metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis at 24 weeks, as compared to merely 19.1% for placebo.

Altimmune shares jumped during after-hours trading on Wednesday after the biotech firm said it would disclose top-line results from its 24-week Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) on Thursday.The stock climbed 7.2% on Tuesday to close at $7.71&nbsp;and extended its rally after hours with a 5.7% gain to $8.15.The upcoming readout is seen as a key milestone for the company’s lead asset, pemvidutide, a GLP-1/glucagon dual receptor agonist being evaluated across multiple liver and metabolic indications, including obesity, alcohol use disorder (AUD), and alcohol-related liver disease (ALD).<a href="https://stocktwits.com/symbol/ALT">Altimmune</a> launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options.&nbsp;The company also plans to begin a Phase 2 study in ALD later this year.Altimmune’s Chief Medical Officer, Scott Harris, previously noted that pemvidutide showed promising reductions in alcohol preference in preclinical models, suggesting potential crossover benefits for metabolic and addictive disorders.Investors will be watching closely on Thursday for signs of efficacy in liver fat reduction, inflammation, and fibrosis, which are endpoints that could position pemvidutide as a competitive candidate in the growing MASH treatment landscape.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said if the data were negative, the company might have quietly published the topline results and followed up later with a management call to explain next steps.&nbsp;<stembedurl>https://stocktwits.com/Micabella/message/619038659</stembedurl>They suggested the only potential delay could be around fibrosis data, which may require the full 48-week readout.Another trader pointed out that if the data were negative, the company might have pushed the announcement into next week’s July 4th holiday lull, when market activity is typically lower.&nbsp;<stembedurl>https://stocktwits.com/Calvary316/message/619038510</stembedurl>Releasing it this Thursday instead, they argued, gives the stock another day to run, a move they believe hints at strong results.The stock has risen 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Altimmune Stock Runs Hot Ahead Of MASH Trial Readout; Retail Bulls Eye Big Win

Altimmune launched the RECLAIM Phase 2 trial of pemvidutide in AUD in May, aiming to reduce alcohol consumption in a population underserved by current treatment options. 

Traders are closely watching Thursday’s topline data for signs that pemvidutide could emerge as a competitive treatment in the growing MASH landscape. 

Shares of Altimmune, Inc. (ALT) were in the spotlight on Tuesday morning after the company reported a narrower first-quarter (Q1) loss that was better than Wall Street expectations and secured up to $100 million in credit.Diluted net loss for the three months ended March 31, 2025, was $0.26 per share, compared to a net loss of $0.34 per share in the same period in 2024, and lower than an estimated loss of $0.34 per share, as per Finchat data.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-first-quarter-2025-financial-results-and">company</a> ended the March quarter with cash, cash equivalents, and short-term investments totaling $150 million.Altimmune also entered into a $100 million credit facility with Hercules Capital on Tuesday, with an initial $15 million tranche funded at closing.The company said that an additional $25 million is available in 2025 at Altimmune’s option, subject to the achievement of certain clinical and financial milestones.Altimmune said the remaining $60 million will be available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to Hercules's approval. &nbsp;The company said the credit facility significantly increases Altimmune’s financial strength and flexibility.CEO Vipin K. Garg said the company is approaching a number of important milestones. In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).Altimmune also intends to commence phase 2 trials to study pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) in the second and third quarter of this year, respectively.On Stocktwits, retail sentiment around Altimmune jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_13_at_10_39_15_AM_png_8bfe41ef98.webp" alt="ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>ALT's Sentiment Meter and Message Volume as of 10:39 a.m. ET on May 13, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> is down by 21% this year and by over 23% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/iteos-gsk-end-collaboration-on-experimental-cancer-therapy/chi8V5tRbZi">iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

An employee pipettes in a laboratory of a biopharmaceutical company | Photo by Bernd Weißbrod/picture alliance via Getty Images

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? 

Shares of Altimmune Inc. are down more than 23% this year, but that has not deterred retail investors from losing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-q4-2024-earnings/chdgfF2RyA">hope</a> in the clinical-stage biotech company.The company has gained traction for its lead candidate,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-on-phase-2-obesity-drug-trial-data/c7zs1ZqRP8">pemvidutide</a>, a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH. In a mid-stage trial, the drug showed that it helped patients reduce their weight by more than 15%.&nbsp;At its R&amp;D Day last week, Altimmune provided more cheer as it unveiled plans to test pemvidutide for treating alcohol use disorder and alcohol-associated liver disease in the second and third quarters of this year.According to The Fly, Evercore ISI said it likes Altimmune's latest expansion and suggested that pemvidutide could rake in more revenue for the new goals than MASH, as 35 million people in the U.S. alone suffer from alcohol use disorder and alcohol-associated liver disease.The research firm added that there is some preclinical and anecdotal evidence to support its thesis.Assuming all goes well, Altimmune will need to fund a Phase 3 program later this year in addition to the AUD/ALD studies, said Evercore, which has an Outperform rating on the shares and a price target of $25.Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. Last year's key&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">C-suite hire</a> at a "pivotal time" for Altimmune bolstered their belief.A Betaville&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.msn.com/en-us/money/companies/altimmune-soars-amid-takeover-speculation/ar-AA1AWioc">report</a> suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms — one FTSE-100 listed, one German, and one U.S.-based — may be involved.<figure class="image"><img style="aspect-ratio:1320/710;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_Stocktwits_poll_on_March_18_png_3a31e58347.webp" alt="ALT Stocktwits poll on March 18.png" width="1320" height="710"><figcaption>ALT Stocktwits poll on March 18. | source: Stocktwits</figcaption></figure>One bullish user said it's "not if, but when [a deal happens]. Too much TAM [total addressable market] for this pipeline of a molecule."<stembedurl>https://stocktwits.com/artiebet/message/608157454</stembedurl>Another user speculated a buyout could happen "within three months," noting the stock is "heading north each week" with "higher lows, higher highs."<stembedurl>https://stocktwits.com/LiveNow1225/message/608159514</stembedurl>Altimmune's stock, which was&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Altimmune Shares Sink In 2025, But Retail Traders Are Optimistic About A Buyout

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.


Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended gains in after-hours trading. Retail buzz on Stocktwits surged, hitting a three-month high.The clinical-stage biopharma company reported a net loss of $23.2 million, or $0.33 per share, for Q4 2024 — an improvement from a $31.6 million loss ($0.54 per share) a year ago.&nbsp;Altimmune ended the year with $132 million in cash and investments, which it expects to fund operations well into the second half of 2026, covering key milestones, including the Phase 2b readout for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) next quarter.CEO Vipin K. Garg said the IMPACT trial was one of "the fastest enrolling biopsy-driven Phase 2b MASH trials, reflecting pemvidutide's appeal due to its potent reduction of liver fat and body weight.""We are confident it will achieve statistically significant improvements in both MASH resolution and fibrosis at trial readout."Altimmune also said it had secured FDA clearance for two additional indications submitted under Investigational New Drug (IND) applications in Q4, with Phase 2 efficacy studies set to begin mid-2025. The company plans to unveil details at its virtual R&amp;D Day on March 13.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume soaring 273% in the 24 hours leading to Thursday's close.&nbsp;<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ALT_sentiment_and_message_volume_Feb_27_1ee28571fe.png" alt="ALT sentiment and message volume Feb 27.png" width="1316" height="316"><figcaption>ALT sentiment and message volume Feb 27 | source: Stocktwits</figcaption></figure>One user predicted a sharp rally to $50, interpreting comments from Altimmune's chief scientific officer that pemvidutide "is the best drug for many indications."<stembedurl>https://stocktwits.com/romanaround/message/606129604</stembedurl>Another speculated on the new INDs, saying they could be for dyslipidemia (or hypertriglyceridemia) and Cirrhosis.<stembedurl>https://stocktwits.com/Cryptobearcat/message/606145193</stembedurl>Altimmune's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist being developed for obesity and MASH.&nbsp;The stock drew attention in December after being <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-rises-after-addition-to-nasdaq-biotech-index/cJaozG7RSI">added</a> to the Nasdaq Biotechnology Index (NBI).Shares of Altimmune are down over 12% year-to-date.&nbsp;According to Koyfin data, eight of the nine analysts covering the stock rate it a 'Buy' or 'Strong Buy,' while one has a 'Hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print

The company plans to unveil details at its virtual R&D Day on March 13.

Shares of Altimmune, Inc. climbed early on Thursday, recovering from a nearly 6% drop in the previous session, drawing significant retail attention.&nbsp;The stock became one of the top three trending symbols on Stocktwits during early trading after the company announced its inclusion in the Nasdaq Biotechnology Index ($NBI) starting Dec. 23.<a href="https://stocktwits.com/news-articles/markets/5/alt-stock-slides-after-new-cfo-retail-raises-speculation/cJ4g6IuRO9">Altimmune</a>, a clinical-stage biotech firm, is currently developing pemvidutide for obesity and metabolic dysfunction-associated steatohepatitis (MASH).&nbsp;CEO Vipin Garg said, “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company.”“With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year,” he added.The Nasdaq Biotechnology Index, established in 1993, tracks the performance of Nasdaq-listed biotech and pharmaceutical companies that meet strict criteria such as market capitalization, trading volume, and seasoning requirements.&nbsp;The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.On Stocktwits, retail sentiment for Altimmune shifted from ‘neutral’ to ‘extremely bullish,’ accompanied by a sharp rise in message volume.&nbsp;<stembedurl>https://stocktwits.com/romanaround/message/597152901</stembedurl><stembedurl>https://stocktwits.com/Designed2Gain/message/597160936</stembedurl>A poll on the platform revealed that 52% of retail investors believe the NBI addition will provide a significant long-term boost to the stock, while 22% expect minimal impact.<a href="https://stocktwits.com/symbol/ALT">Altimmune’s shares</a> got a boost last month following better-than-expected quarterly&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/altimmune-q3-loss-narrows/cJ40TqmROm">earnings</a> and positive updates on pemvidutide.&nbsp;The company reported a successful FDA meeting that finalized its Phase 3 obesity program design, with no major safety concerns raised.&nbsp;Analysts like H.C. Wainwright’s Patrick Trucchio have expressed confidence in the drug’s differentiation within the GLP-1 agonist space, citing robust efficacy attributes and a well-defined clinical program.Still, Altimmune’s stock remains down nearly 30% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Nasdaq company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.26	--	--	N/A
Q3 '25	-$0.27	-$0.21	22.83%	BEAT
Q2 '25	-$0.34	-$0.27	19.70%	BEAT
Q1 '25	-$0.35	-$0.26	26.12%	BEAT
Q4 '24	-$0.33	-$0.33	0.75%	BEAT

ALT
Altimmune Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest ALT News

ALTAltimmune Inc